Cardiac phenotypes and cardiovascular risk in people with type 2 diabetes mellitus and chronic coronary artery disease: A Chinese retrospective cohort study
Abstract
Background: Patients with type 2 diabetes mellitus (T2DM) and chronic coronary artery disease (CAD) are at very high risk of major adverse cardiovascular events (MACE), but further risk stratification remains challenging.
Aims: This study aimed to use cluster analysis to identify cardiac phenotypes associated with cardiovascular risk in T2DM and chronic CAD populations.
Methods: Cluster analysis was performed on 12 echocardiographic variables, including aortic and pulmonary artery diameters, atrial and ventricular dimensions, interventricular septum and posterior wall thicknesses, ejection fraction, and blood flow velocities in 1633 Chinese individuals. Survival outcomes were analyzed using Kaplan–Meier methods, Cox proportional hazards models, and restricted cubic splines.
Results: Two distinct phenotypes were identified. Patients in cluster 2 were characterized by larger atrial and ventricular volumes, thicker interventricular septum and posterior walls, higher ventricular mass index, and faster aortic blood flow velocity, summarized as “larger, thicker, faster”. Over a median 15-month follow-up, patients in cluster 2 exhibited higher MACE risk (HR, 1.35; 95% CI, 1.17–1.57), particularly for heart failure hospitalization (HR, 1.37; 95% CI, 1.15–1.64). Consistent results were observed in sex and hypertension subgroups. Fibrinogen ≥3.8 g/l, uric acid ≥329.2 mmol/l, high-density lipoprotein cholesterol ≤1.07 mmol/l, low-density lipoprotein cholesterol ≥2.5 mmol/l, and hemoglobin ≤132 g/l were demonstrated statistically risk factors for MACE in cluster 2.
Conclusions: Cluster analysis of echocardiographic variables may improve the identification of higher risk patients and highlighted the prognostic value of cardiac remodeling in T2DM and chronic CAD populations.
Keywords: cardiovascular prognosischronic coronary artery diseasecluster analysisechocardiographytype 2 diabetes mellitus
References
- Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet] 10th ed. Brussels: International Diabetes Federation, 2021.
- Marx N, Federici M, Schütt K, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043–4140.
- Zellweger MJ, Pfisterer ME, Pfisterer ME, et al. Management of stable coronary artery disease. Lancet. 2010; 375(9716): 763–772.
- Cavender MA, Steg PhG, Smith SC, et al. REACH Registry Investigators. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015; 132(10): 923–931.
- Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
- Fox KAA, Metra M, Morais J, et al. The myth of 'stable' coronary artery disease. Nat Rev Cardiol. 2020; 17(1): 9–21.
- Tsao CW, Gona PN, Salton CJ, et al. Left ventricular structure and risk of cardiovascular events: a framingham heart study cardiac magnetic resonance study. J Am Heart Assoc. 2015; 4(9): e002188.
- Kawel-Boehm N, Kronmal R, Eng J, et al. Left ventricular mass at MRI and long-term risk of cardiovascular events: the multi-ethnic study of atherosclerosis (MESA). Radiology. 2019; 293(1): 107–114.
- Russo C, Jin Z, Homma S, et al. Effect of diabetes and hypertension on left ventricular diastolic function in a high-risk population without evidence of heart disease. Eur J Heart Fail. 2010; 12(5): 454–461.
- Tay JCK, Chia SY, Sim DKL, et al. Interaction of sex and diabetes in Asian patients with heart failure with mildly reduced left ventricular ejection fraction. Ann Acad Med Singap. 2022; 51(8): 473–482.
- Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014; 383(9933): 1973–1980.
- Ohkuma T, Komorita Y, Peters SAE, et al. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019; 62(9): 1550–1560.
- Avogaro A, Giorda C, Maggini M, et al. Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007; 30(5): 1241–1247.
- González-Juanatey C, Anguita-Sánchez M, Barrios V, et al. Impact of advanced age on the incidence of major adverse cardiovascular events in patients with type 2 diabetes mellitus and stable coronary artery disease in a real-world setting in Spain. J Clin Med. 2023; 12(16).
- Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004; 116 Suppl 5A: 30S–38S.
- Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016; 118(11): 1723–1735.
- Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018; 6(5): 361–369.
- Sharma A, Zheng Y, Ezekowitz JA, et al. Cluster analysis of cardiovascular phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine. Diabetes Care. 2022; 45(1): 204–212.
- Flores AM, Schuler A, Eberhard AV, et al. Unsupervised learning for automated detection of coronary artery disease subgroups. J Am Heart Assoc. 2021; 10(23): e021976.
- Jiang Yu, Yang ZG, Wang J, et al. Unsupervised machine learning based on clinical factors for the detection of coronary artery atherosclerosis in type 2 diabetes mellitus. Cardiovasc Diabetol. 2022; 21(1): 259.
- Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023; 176(3): 381–387.
- Wang Z, Wang C, Xie Z, et al. Echocardiographic phenotypes of Chinese patients with type 2 diabetes may indicate early diabetic myocardial disease. ESC Heart Fail. 2022; 9(5): 3327–3344.
- Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977; 55(4): 613–618.
- Dempster AP, Laird NM, Rubin DB. Maximum Likelihood from Incomplete Data Via the EM Algorithm. Journal of the Royal Statistical Society: Series B (Methodological). 2018; 39(1): 1–22.
- Huang Z. Extensions to the k-Means Algorithm for Clustering Large Data Sets with Categorical Values. Data Mining and Knowledge Discovery. 1998; 2(3): 283–304.
- Charrad M, Ghazzali N, Boiteau V, et al. NbClust: an R package for determining the relevant number of clusters in a data set. Journal of Statistical Software. 2014; 61(6): 1–36.
- Malik ME, Andersson C, Blanche P, et al. Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes. Clin Res Cardiol. 2023; 112(2): 215–226.
- Yacamán Méndez D, Zhou M, Trolle Lagerros Y, et al. Characterization of data-driven clusters in diabetes-free adults and their utility for risk stratification of type 2 diabetes. BMC Med. 2022; 20(1): 356.
- Wang J, Liu JJ, Gurung RL, et al. Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes. Diabetologia. 2022; 65(12): 2146–2156.
- Chen Y, Zheng Y, Lip GYH. Leveraging machine learning for enhanced mortality risk prediction in atrial fibrillation: A step towards precision medicine? Pol Heart J. 2024; 82(10): 921–923.
- Völzke H, Schmidt CO, Baumeister SE, et al. Personalized cardiovascular medicine: concepts and methodological considerations. Nat Rev Cardiol. 2013; 10(6): 308–316.
- Ernande L, Audureau E, Jellis CL, et al. Clinical Implications of Echocardiographic Phenotypes of Patients With Diabetes Mellitus. J Am Coll Cardiol. 2017; 70(14): 1704–1716.
- Echouffo-Tcheugui JB, Musani SK, Bertoni AG, et al. Patients phenotypes and cardiovascular risk in type 2 diabetes: the Jackson Heart Study. Cardiovasc Diabetol. 2022; 21(1): 89.
- Dennis JM, Shields BM, Henley WE, et al. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019; 7(6): 442–451.
- Gjesdal O, Bluemke DA, Lima JA. Cardiac remodeling at the population level - risk factors, screening, and outcomes. Nat Rev Cardiol. 2011; 8(12): 673–685.
- Horio T, Miyazato J, Kamide K, et al. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens. 2003; 16(11 Pt 1): 938–944.
- Celentano A, Crivaro M, Roman MJ, et al. eft ventricular geometry and arterial function in hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2001; 11(5): 312–319.
- Anzai T. Inflammatory Mechanisms of Cardiovascular Remodeling. Circ J. 2018; 82(3): 629–635.
- Fonseca FA, Izar MC. Role of inflammation in cardiac remodeling after acute myocardial infarction. Front Physiol. 2022; 13: 927163.
- Wełnicki M, Gorczyca-Głowacka I, Mamcarz A, et al. The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiol Pol. 2022; 80(12): 1286–1289.
- Biter HI, Cakal S, Cakal B, et al. The impact of using SGLT-2 inhibitor on left ventricular longitudinal strain and NT-proBNP levels during six-month follow-up in diabetic patients with and without coronary artery disease with preserved ejection fraction. Pol Heart J. 2024; 82(6): 640–646.
